Dylan Beynon: At-Home Ketamine Therapy, Big Pharma Pushback, and the Future of Psychedelic Accessibility
In this episode, Joe Moore welcomes Dylan Beynon, CEO and Founder of Mindbloom, one of the largest providers of legal, at-home ketamine therapy in the U.S.
Dylan shares the deeply personal story that led him to psychedelic medicine—including the tragic loss of his mother and sister to addiction and mental illness—and how these experiences continue to fuel his mission to make psychedelic therapy affordable and accessible for all. Mindbloom has now facilitated over 654,000 sessions across 38 states, offering both sublingual and subcutaneous (injectable) ketamine in a comprehensive treatment program that includes preparation, integration, music, journaling, and even generative AI art.
The conversation dives into common criticisms of at-home ketamine, the benefits of guided treatment over IV infusions, and the disturbing influence of Big Pharma in media narratives—especially the growing PR push behind SPRAVATO. Dylan also breaks down what makes Mindbloom’s outcomes stand out, why they recently added injectable ketamine, and how their safety data challenges popular misconceptions.
Joe and Dylan also touch on the potential future of at-home MDMA therapy, regulatory hurdles, and what it will take to scale these powerful treatments to millions of people in need.
If you're in the psychedelic field, considering ketamine therapy, or curious about the ethics and economics of psychedelic medicine, this episode offers a powerful look behind the curtain.
Resources:
